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. 54  Abstract   
. 55  Background: Adrenocortical carcinoma (ACC) is a rare 
endocrine malignancy with overall   
. 56  poor prognosis. The Ki67 labeling index (LI) has a major 
prognostic role in localized ACC   
. 57  after complete resection but its estimates may suffer from 
considerable intra- and   
. 58  interobserver variability. VAV2 overexpression induced by 
increased SF-1 dosage is an   
. 59  essential factor driving ACC tumor cell invasion.   
. 60  Objective: To assess the prognostic role of VAV2 expression 
in ACC by investigation of a   
. 61  large cohort of patients.   
. 62  Design, Setting and Participants: 171 ACC cases (157 
primary tumors, 6 local   
. 63  recurrences, 8 metastases) from seven ENS@T centers were 
studied.   
. 64  Outcome Measurements: H-scores were generated 
quantifying VAV2 expression. VAV2   
. 65  expression was divided into two categories, low (H-score <2) 
and high (H-score ≥2). Ki67   
. 66  LI retrieved from patients' pathological records was also 
categorized into low (<20%) and   
. 67  high (≥20%). Clinical and immunohistochemical markers were 
correlated with progression-   
. 68  free (PFS) and overall survival (OS).   
. 69  Results: VAV2 expression and Ki67 LI were significantly 
correlated with each other and   
. 70  with PFS and OS. Heterogeneity of VAV2 expression inside 
the same tumor was very low.   
. 71  Combined assessment of VAV2 expression and Ki67 LI 
allowed to improve patient   
. 72  stratification to low-risk and high-risk groups.   
. 73  Conclusion: Combined assessment of Ki67 LI and VAV2 
expression improves prognostic   
. 74  prediction in ACC.   
75 76  
77 78 79  
3  
. 79  Introduction   
. 80  Adrenocortical carcinoma (ACC) is a rare endocrine 
malignancy with overall poor   
. 81  prognosis, limited treatment options when progressed into 
metastatic stage and   
. 82  unsatisfactory response to polychemotherapeutic cytotoxic 
regimens (1, 2). Hence the   
. 83  most efficient method to eradicate the disease consists in 
complete surgical resection of   
. 84  the primary tumor. However, risk of recurrence is high even in 
this condition. Molecular   
. 85  studies have identified two subclasses of ACCs with 
aggressive (C1A) or indolent (C1B)   
. 86  clinical behavior, respectively (3-6). However, since molecular 
markers identified by those   
. 87  studies have not yet found entrance into clinical practice, it 
would be of particular   
. 88  importance to stratify patients with ACC into low-or high-risk 
groups to adequately monitor   
. 89  disease recurrence and assign them to appropriate 
therapeutic interventions. The   
. 90  histological Weiss score, which is commonly used as an 
established morphometric   
. 91  criterion for the differential diagnosis in adrenocortical tumors, 
has limited value as a   
. 92  prognostic indicator, especially in cases with borderline 
features (7, 8). Conversely, it was   
. 93  shown that a number of immunohistochemical markers have a 
prognostic value in ACC (9-   
. 94  18). Among those, the most widely used in clinical pathology 
reports is the Ki67 labeling   
. 95  index (LI), which is directly related to the proliferative activity of 
a given tissue (14-18). A   
. 96  study recently completed by the European Network for the 
Study of Adrenal Tumors   
. 97  (ENS@T) could indeed demonstrate that Ki67 LI has a major 
prognostic role in localized   
. 98  ACC after complete resection (18). However, Ki67 LI 
estimates suffer from considerable   
. 99  intra- and interobserver variability, as highlighted in a recent 
study (19). New prognostic   
. 100  markers are therefore needed to further refine prognostic 
classification of patients with   
. 101  ACC as part of a multiparametric analysis.   
4  
. 102  The transcription factor Steroidogenic Factor-1 has a pivotal 
role in regulating   
. 103  adrenocortical cell proliferation and differentiation (20). Its 
overexpression is associated to   
. 104  adrenocortical tumorigenesis through regulation of a specific 
set of SF-1 dosage-   
. 105  dependent target genes (21, 22). One of these genes 
encodes VAV2, a guanine   
. 106  nucleotide exchange factor (GEF) for small GTPases of the 
Rho family (23). We have   
. 107  recently shown that VAV2 overexpression induced by an 
increased SF-1 dosage in ACC   
. 108  is an essential factor driving tumor cell invasion (24). Herein, 
we present the results of a   
. 109  large study involving ACC cases provided by seven 
European institutions aimed to assess   
. 110  the prognostic value of VAV2 expression in ACC and to 
compare and integrate it with the   
. 111  Ki67 LI.   
112 113  
. 114  Materials and Methods   
. 115  Immunostaining on formalin-fixed, paraffin embedded 
ACC samples   
. 116  We analyzed a total of 171 adrenocortical tumor tissues from 
patients with ACC   
. 117  provided by seven ENS@T centers (Italy 103, The 
Netherlands 42, France 20, Germany 6   
. 118  samples). 145 samples were previously assembled in 7 
tissue microarrays (TMA) with 2 or   
. 119  3 cores per sample, interspersed with normal human liver, 
kidney and placenta tissues,   
. 120  and 26 samples were available as full slides. Among the 
ACC samples, 157 samples   
. 121  derived from primary tumors (male/female 59/98, average 
age±SD 48.7±15.2 years,   
. 122  average tumor size±SD 11.2±5.4 cm; for patients' 
characteristics see Table S1), 6 from   
. 123  local recurrences and 8 from distant metastases (liver and 
lung). The diagnosis of ACC   
. 124  was made by established criteria based on clinical, 
biochemical and morphological data   
5  
. 125  (25). All clinical data were collected through the ENS@T 
database (registry.ensat.org). All   
. 126  patients gave informed consent and the study was approved 
by ethical committees from   
. 127  all participating institutions. Immunohistochemical detection 
was performed in all samples   
. 128  using an indirect immunoperoxidase technique after high 
temperature antigen retrieval in   
. 129  0.01 M citrate buffer (pH 6.5) in a pressure-cooker for 13 
minutes. The primary antibody   
. 130  was a rabbit monoclonal antibody against the VAV2 protein 
(clone EP1067Y, ab52640   
. 131  Abcam) diluted 1:250 in 25% AB serum in PBS and 
incubated 1 h at RT. Signal detection   
. 132  was performed with the Advance HRP detection system 
(Dako) and DAB chromogen   
. 133  according to the manufacturer’s instructions. Nuclei were 
counterstained with Mayer’s   
. 134  hematoxylin for 3 minutes. As negative control, universal 
rabbit negative control (Dako)   
. 135  was used. Immunostaining results were analyzed using a 
light microscope at high   
. 136  magnification. VAV2 staining intensity was evaluated 
independently by two investigators   
. 137  blinded to the clinical data (S.S. and I.S.). Cytoplasmic 
staining intensity was evaluated   
. 138  with a grading score of 0, 1, 2 or 3, corresponding to 
negative, weak, moderate and strong   
. 139  intensity, respectively. The proportion of positive tumor cells 
was calculated for each   
. 140  specimen and set up to be scored 0, 0.1, 0.5 or 1, if 0%, 1-
9%, 10-49% or >50% of the   
. 141  tumor cells were positive for VAV2, respectively. A semi-
quantitative H-score was then   
. 142  calculated by multiplying the staining intensity grade by the 
proportion score (12, 24). In all   
. 143  cases analyzed, the proportion of VAV2 positive cells was 
always >50%, so all intensity   
. 144  values were multiplied by a factor equal to 1 to yield the H-
score. The cut-off point to   
. 145  separate samples in high or low VAV2 expression was 
between H-scores <2 and ≥2. Ki67   
. 146  LI data assessed by the local pathologists in each expert 
center were retrieved from the   
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. 147  ENS@T database. The Ki67 LI cut-off value used in this 
study to separate low LI and high   
. 148  LI groups was 20%.   
149  
. 150  Statistical analysis   
. 151  Correlation analyses were performed using a ⎟2 test for 
categorical variables. The   
. 152  inter-observer agreement for the scoring system was 
evaluated using Cohen’s kappa-   
. 153  coefficient and confirmed using Pearson’s correlation 
coefficient. As cutoff for strong   
. 154  agreement 0.81 was chosen for the kappa-coefficient and 
0.75 for Pearson’s coefficient   
. 155  (26). The comparison of clinical and histopathological 
characteristics was performed on   
. 156  GraphPad Prism 6.0 software using non-parametric Mann-
Whitney test (for two groups)   
. 157  and Kruskal-Wallis test with Dunn's correction for multiple 
testing (for more than two   
. 158  groups), as appropriate. A p value <0.05 was considered to 
be statistically significant.   
. 159  Survival analysis for ACC patients was calculated as 
described (24) using the Kaplan-   
. 160  Meier method and differences between groups were 
assessed with log-rank and Cox   
. 161  proportional hazards statistics, using the SPSS software 
package (version 23.0.0 for Mac),   
. 162  after adjustment for sex, age and tumor stage. Progression-
free survival (PFS) was   
. 163  defined as time elapsed from primary resection of ACC to the 
first recurrence, loco-   
. 164  regional or systemic. Overall survival (OS) was defined as 
time elapsed from primary   
. 165  resection of ACC to disease-related death or last follow-up 
visit. In the group of patients   
. 166  with R0 resection, OS data were available for 100 (VAV2) 
and 105 (Ki67 LI) patients,   
. 167  respectively. 92 of those patients had both VAV2 and Ki67 LI 
OS data available. Viable   
. 168  cell data after VAV2 knockdown were analyzed by 1-way 
ANOVA with Dunnett's   
. 169  correction for multiple comparisons.   
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. 171  Results   
. 172  VAV2 expression is a strong predictor of PFS and OS in 
ACC patients   
. 173  Examples of different VAV2 expression patterns in ACC are 
shown in Fig. 1. A H-   
. 174  score was assigned to each sample, which took in 
consideration both staining intensity   
. 175  and the percentage of cells stained by the anti-VAV2 
antibody. The inter-observer   
. 176  agreement was very good with Cohen’s kappa coefficient 
equal to 0.85 (95%CI: 0.72-   
. 177  0.89) and Pearson coefficient r=0.90 (95%CI:0.86-0.93), 
p<0.001. In contrast to Ki67   
. 178  staining, which is usually heterogeneous throughout a tumor, 
VAV2 expression was fairly   
. 179  equally distributed within a given tumor, with all samples 
presenting a percentage of   
. 180  stained cells >50%. H-score heterogeneity among different 
TMA tissue cores belonging to   
. 181  the same tumors was limited, with a residual standard 
deviation σ=0.14 and an intra-class   
. 182  correlation coefficient α=0.95 (95%CI: 0.92-0.97) (Fig. S1). 
The same homogenous   
. 183  distribution was also observed when whole tumor slides were 
analyzed (Fig. 1). VAV2   
. 184  expression in the tumor was strongly correlated to both PFS 
(Fig. 2A) and OS (Fig. 2B),   
. 185  confirming the results of our previous study performed on an 
independent smaller cohort   
. 186  of ACC patients (24). Patients with strong VAV2 expression 
had a 2.8-fold higher risk to   
. 187  experience a recurrence and 1.6-fold increased risk to die. 
No statistically significant   
. 188  difference existed for VAV2 expression in primary tumors and 
metastatic sites from the   
. 189  same patients (p=0.67). The Ki67 LI was also a strong 
predictor of PFS (Fig. 2C) and OS   
. 190  (Fig. 2D), as reported in previous studies (14-18). Both VAV2 
expression and Ki67 LI were   
. 191  strongly correlated with OS even in patients with R0 
resection (Fig. S2). VAV2 expression   
8  
. 192  and Ki67 LI had a similar strong prognostic value for PFS 
and OS both in univariate and in   
. 193  multivariate analysis, taking into account patients' age, sex 
and tumor stage (Table 1).   
194  
. 195  Combined assessment of VAV2 expression and Ki67 LI 
improves prognostic power   
. 196  In general, a significant correlation existed between Ki67 LI 
and VAV2 expression   
. 197  in our ACC cohort (Fig. S3). A strong correlation also existed 
when Ki67 LI and VAV2   
. 198  expression were considered as categorical (low vs. high) 
variables (⎟2 = 6.18, p=0.01).   
. 199  However, in several cases these two parameters were 
dissociated with one value being   
. 200  elevated and the other low in the same tumor. Remarkably, 
in those patients PFS and OS   
. 201  were intermediate between the high-risk (high VAV2 
expression-high Ki67 LI) and the low-   
. 202  risk groups (low VAV2 expression-low Ki67 LI) (Fig. 3A, B). 
Merging the groups with high   
. 203  VAV2-low Ki67 LI and low VAV2-high Ki67 LI and comparing 
them to the high VAV2-high   
. 204  Ki67 LI and low VAV2-low Ki67 LI groups identified three 
classes of patients with very   
. 205  different RFS (159.7±23.2, 90.3±15.7 and 20.8±5.8 months, 
respectively) and OS   
. 206  (203.7±29.6, 130.3±29.6 and 41.6±5.1 months, respectively) 
(Fig. 3C, D). This type of   
. 207  stratification maintained a strong prognostic value even in R0 
patients (Fig. S4).   
. 208  Remarkably, when considering the high-risk group apart from 
all other patients with ACC,   
. 209  a very strong correlation existed with OS in the whole cohort 
(Fig. 4A) and with both PFS   
. 210  and OS in R0 patients (Fig. 4B, C). Furthermore, isolated 
high VAV2 expression or high   
. 211  Ki67 LI showed a prediction value for worse PFS and OS that 
was slightly lower compared   
. 212  with the combination of both high VAV2 expression + high 
Ki67 LI [PFS: 22 months,   
. 213  HR=0.67 (VAV2) and 28 months, HR=0.66 (Ki67 LI) vs. 9 
months for the combination; OS:   
9  
. 214  66 months, HR=0.73 (VAV2) and 40 months, HR=0.82 (Ki67 
LI) vs. 33 months for the   
. 215  combination].   
216  
. 217  Discussion   
. 218  The prognosis of ACC patients is variable and poorly 
predictable. A recent large   
. 219  multicentric ENS@T study has shown that the KI67 LI is the 
most powerful parameter   
. 220  predicting disease recurrence and survival in ACC patients 
after complete tumor resection   
. 221  (18). The Ki67 LI has been integrated with the combined 
evaluation of morphological   
. 222  parameters (number of mitoses/presence of necrosis) in the 
newly introduced Helsinki   
. 223  score, which reportedly is able to more accurately predict 
recurrence in ACC (8, 27).   
. 224  However, even if Ki67 LI assessment is routinely performed 
in diagnostic pathology   
. 225  laboratories for a large number of neoplastic disorders, its 
standardization and   
. 226  reproducibility have been questioned for many tumor types, 
including ACC (19). It is   
. 227  therefore important to identify other molecular markers that 
can complement the Ki67 LI to   
. 228  obtain a more accurate stratification of the risk of recurrence 
in patients with ACC. In this   
. 229  perspective, molecular prognostic indicators derived from 
genomic studies are very   
. 230  promising (3, 28, 29), but for routine implementation they 
suffer from the important   
. 231  drawback that, at least at the present state of technology, 
frozen tumoral material is   
. 232  required. On the other hand, prognostic value of circulating 
markers of malignancy awaits   
. 233  validation in large cohorts of ACC patients (30-33).   
. 234  We have recently shown that VAV2 overexpression is an 
essential driver of cell   
. 235  invasion in conditions of increased SF-1 dosage through its 
GEF activity for the small   
. 236  GTPases Rac1 and Cdc42 (24). Those data directly link 
VAV2 with the potential   
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. 237  mechanism of malignancy consisting in increased cellular 
invasiveness. In the present   
. 238  study we extended the previous study to a large European 
cohort of patients with ACC   
. 239  and show that the tumor VAV2 H-score is significantly 
correlated to PFS and OS. The   
. 240  combined assessment of VAV2 expression and Ki67 LI 
improves patient risk stratification,   
. 241  with cases presenting high Ki67 LI but low VAV2 expression 
having significantly longer   
. 242  PFS and OS compared to patients with concordant high-risk 
parameters. In our study,   
. 243  VAV2 H-score assessment, which was mainly performed on 
TMA tissue cores, was   
. 244  associated to an excellent intratumoral reproducibility and is 
then in principle less prone to   
. 245  intra- and interobserver variability, although further work is 
needed to specifically address   
. 246  this question on an even larger number of cases. These 
results show that   
. 247  immunohistochemical assessment of VAV2 expression may 
usefully complement the   
. 248  measurement of the Ki67 LI for prognostic stratification of 
patients with ACC.   
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Figure legends  
Figure 1. Examples of various intensities of VAV2 staining in 
ACC specimens. H-score value is indicated for each image, 
respectively. Scale bar, 400 ⎧m (images in left column); 50 ⎧m 
(images in right column).  
Figure 2. Correlation of VAV2 expression (H-score) and Ki67 LI 
with PFS and OS in our ACC series. (A) PFS in low VAV2 
expression (H-score <2) group (green line) 127±15.9 months; high 
VAV2 expression (H-score ≥2) group (red line) 25.7±4.1 months. 
p<0.001, Kaplan-Meier method. (B) OS in low VAV2 expression (H-
score <2) group (green line) 180±22 months; high VAV2 expression 
(H-score ≥2) group (red line) 87.4±13 months. p=0.001, Kaplan-
Meier method. (C) PFS in low Ki67 LI (<20%) group (green line) 
137±17.9 months; high Ki67 LI (≥20%) group (red line) 68.5±14.3 
months. p<0.001, Kaplan-Meier method. (D) OS in low Ki67 LI 
(<20%) group (green line) 187.5±22.9 months; high Ki67 LI (≥20%) 
group (red line) 96.2±17 months. p=0.001, Kaplan-Meier method. 
The numbers of cases analyzed for each group are reported in 
parentheses.  
Figure 3. Correlation of combined VAV2 expression (H-score) 
and Ki67 LI with PFS and OS in our ACC series. (A) PFS in low 
VAV2 expression (H-score <2)-low Ki67 LI (<20%) group (green 
line) 159.7±23.2 months; high VAV2 expression (H-score ≥2)-low 
Ki67 LI (<20%) group (yellow line) 50.7±8.4 months;  
low VAV2 expression (H-score <2)-high Ki67 LI (≥20%) group (pale 
green line) 96.6±26.3 months; high VAV2 expression (H-score ≥2)-
high Ki67 LI (≥20%) group (red line) 20.8±5.8 months. Compared to 
low VAV2-low Ki67 LI: high VAV2-low Ki67 LI HR=2.55 (1.09-5.97), 
p=0.030; low VAV2-high Ki67 LI HR=2.46 (0.97-6.23), p=0.058; 
high VAV2-high Ki67 LI HR=6.75 (2.97-15.31), p<0.001; Kaplan-
Meier method. (B) OS in low VAV2 expression (H-score <2)-low 
Ki67 LI (<20%) group (green line) 203.7±29.6 months; high VAV2 
expression (H- score ≥2)-low Ki67 LI (<20%) group (yellow line) 
120.4±20.5 months; low VAV2 expression (H-score <2)-high Ki67 LI 
(≥20%) group (pale green line) 126±26.7 months; high VAV2 
expression (H-score ≥2)-high Ki67 LI (≥20%) group (red line) 
41.6±5.1 months. Compared to low VAV2-low Ki67 LI: high VAV2-
low Ki67 LI HR=2.66 (1.08-6.52), p=0.032; low VAV2-high Ki67 LI 
HR=3.51 (1.38-8.91), p=0.008; high VAV2-high Ki67 LI HR=5.38 
(2.33-12.40), p<0.001; Kaplan-Meier method. (C) PFS in low VAV2 
expression (H-score <2)-low Ki67 LI (<20%) group (green line) 
159.7±23.2 months; high VAV2 expression (H-score ≥2)-high Ki67 
LI (≥20%) group (red line) 20.8±5.8 months; all other patients with 
dissociated VAV2 expression-Ki67 LI group (grey line) 90.3±15.7 
months. Compared to low VAV2-low Ki67 LI: other HR=2.51 (1.17-
5.39), p=0.018; high VAV2-high Ki67 LI HR=6.75 (2.97-15.31), 
p<0.001; Kaplan-Meier method. (D) OS in low VAV2 expression (H-
score <2)-low Ki67 LI (<20%) group (green line) 203.7±29.6 
months; high VAV2 expression (H-score ≥2)-high Ki67 LI (≥20%) 
group (red line) 41.6±5.1 months; all other patients with dissociated 
VAV2 expression-Ki67 LI group (grey line) 130.3±18.1 months. 
Compared to low VAV2-low Ki67 LI: other  
20  
HR=2.99 (1.32-6.73), p=0.008; high VAV2-high Ki67 LI, HR=5.38 
(2.33-12.40), p<0.001; Kaplan-Meier method. The numbers of 
cases analyzed for each group are reported in parentheses.  
Figure 4. Prognosis of high-risk (high VAV2 expression-high 
Ki67 LI) vs. other ACC patients. (A) OS in the whole cohort of 
ACC patients for the high VAV2 expression (H-score ≥2)-high Ki67 
LI (≥20%) group (red line) 41.5±5 months; all other patients (green 
line) 175.5±19.8 months. p<0.001, Kaplan- Meier method. (B) PFS 
in R0 patients for the high VAV2 expression (H-score ≥2)-high Ki67 
LI (≥20%) group (red line) 20.8±5.8 months; all other patients 
(green line) 127.3±15.7 months. p<0.001, Kaplan-Meier method. 
(C) OS in R0 patients for the high VAV2 expression (H-score ≥2)-
high Ki67 LI (≥20%) group (red line) 47.5±6 months; all other 
patients (green line) 194.8±21.7 months. p=0.005, Kaplan-Meier 
method. The numbers of cases analyzed for each group are 
reported in parentheses.  
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